Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib in IDH1-mutated cholangiocarcinoma
NCT06081829Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivosidenib in cholangiocarcinoma (CCA), sponsored by Servier. Primary endpoint: 6-month Progression Free Survival Rate. Started Oct 2023; status: active, not recruiting.
02
Drugs
ivosidenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06081829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081829.